Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites

European Journal of Cancer Part A

Volumn 32, Issue 8, 1996, Pages 1382-1387

  Boven, E ^a   De Jong, J ^a,c   Kuiper, C M ^a   Bast, A ^b   Van Der Vijgh, W J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c NONE   (Netherlands)

Author keywords

4' Epidoxorubicin; Anthracyclines; Daunorubicin; Doxorubicin; Drug exposure; In vivo efficacy

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DAUNORUBICIN; DOXORUBICIN; DRUG METABOLITE; EPIRUBICIN; LEURUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; DRUG DISTRIBUTION; DRUG SENSITIVITY; DRUG TISSUE LEVEL; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030056811     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00110-4     Document Type: Article

References (25)

1. Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med 1981, 305, 139-153.
2. Olson RD, Mushlin PS, Brenner DE, et al. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 1988, 85, 3585-3589.
3. Olson RD, Mushlin P. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990, 4, 3076-3086.
4. De Jong J, Schoofs PR, Snabilié AM, Bast A, Van der Vijgh WJF. The role of biotransformation in anthracycline-induced cardiotoxicity in mice. J Pharmacol Exp Ther 1993, 266, 1312-1320.
5. Cersosimo RJ, Hong WK. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 1986, 4, 425-439.
6. Masquelier M, Baurain R, Trouet A. Amino acid and dipeptide derivatives of daunorubicin I. Synthesis, physicochemical properties, and lysosomal digestion. J Med Chem 1980, 23, 1166-1170.
7. Baurain R, Masquelier M, Deprez-de Campeneere D, Trouet A. Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumour activity on L1210 leukemic cells in vitro and in vivo. J Med Chem 1980, 23, 1171-1174.
8. Boven E, Hendriks HR, Erkelens CAM, Pinedo HM. The antitumour effects of the prodrugs N-1-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts. Br J Cancer 1992, 66, 1044-1047.
9. De Jong J, Schoofs PR, Onderwater RCA, Pinedo HM, Van der Vijgh WJF, Bast A. Isolated mouse atrium as a model to study anthracycline cardiotoxicity: the role of the β-adrenoceptor system and reactive oxygen species. Res Comm Chem Pathol Pharmacol 1990, 68, 275-291.
10. Soule HD, Vazquez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973, 51, 1409-1416.
11. Matsuoka Y, Moore GE, Yagi Y, Pressman D. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med 1967, 125, 1246-1250.
12. Eva A, Robbins KC, Andersen PR, et al. Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. Nature 1982, 295, 116-119.
13. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983, 65, 55-63.
14. Boven E, Schlüper HMM, Erkelens CAM, Pinedo HM. Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer. Eur J Cancer 1990, 26, 893-986.
15. Maessen P, Pinedo HM, Mross K, Van der Vijgh WJF. New method for the determination of doxorubicin, 4′-epidoxorubicin and all known metabolites in cardiac tissue. J Chromatogr 1988, 424, 103-110.
16. Van der Vijgh WJF, Maessen PA, Pinedo HM. Comparative metabolism and pharmacokinetics of doxorubicin and 4′-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice. Cancer Chemother Pharmacol 1990, 26, 9-12.
17. De Jong J, Maessen PA, Akkerdaas A, Cheung S-F, Pinedo HM, Van der Vijgh WJF. Sensitive method for the determination of daunorubicin and all its known metabolites in plasma and heart by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1990, 529, 359-368.
18. De Jong J, Klein I, Bast A, Van der Vijgh WJF. Analysis and pharmacokinetics of N-1-leucyldoxorubicin and metabolites in tissues of tumour-bearing BALB/c mice. Cancer Chemother Pharmacol 1992, 31, 156-160.
19. De Jong J, Munniksma CN, Guérand WS, Bast A, Van der Vijgh WJF. Fully automated determination of the new anthracycline N-1-leucyldoxorubicin and six metabolites in plasma by high-performance and liquid chromatography with on-line sample handling. J Chromatogr 1992, 574, 273-281.
20. Schott B, Robert J. Comparative activity of anthracycline 13-dihydro metabolites against rat glioblastoma cells in culture. Biochem Pharmacol 1989, 38, 4069-4074.
21. Ferrazzi E, Woynarowski JM, Arakali A, Brenner DE, Beerman TA. DNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics, doxorubicin and idarubicin. Cancer Commun 1991, 3, 173-180.
22. Casazza AM. Experimental evaluation of anthracycline analogs. Cancer Treat Rep 1979, 63, 835-844.
23. De Jong J, Geijssen GJ, Munniksma CN, Vermorken JB, Van der Vijgh WJF. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-1-leucyldoxorubin and its metabolites in a phase I clinical trial. J Clin Oncol 1992, 10, 1897-1906.
24. Boven E. Analogs of conventional agents. In Boven E, Winograd B, eds. The Nude Mouse in Oncology Research. CRC Press, Boca Raton, Florida, 1991, 185-198.
25. Bennis S, Garcia C, Robert J. Aspects of the cellular pharmacology of N-1-leucyldoxorubicin in human tumour cell lines. Biochem Pharmacol 1993, 45, 1929-1931.